BBIO PDUFA decision: Saturday, May 8, 2027

…442_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1   BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1   - PDUFA target action date of May 8, 2027   - If approved, encaleret will be the first and only approved therapy specifically indicated for individuals living with ADH1, repr

Dates are sourced from official registries and filings and can change — estimated dates (marked ~) slip routinely. This page updates automatically when the source registry moves the date. Research information only, not investment advice.